Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309741 | 0.89 | ACE2 (0.72) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL13520192 | 0.89 | TSHR (0.49) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL535923 | 0.89 | ALDH1A1 (0.57) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL15125105 | 0.89 | KDM1A (0.46) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL8309738 | 0.89 | KDM1A (0.46) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL3523671 | 0.89 | KDM1A (0.46) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL18024084 | 0.89 | KDM1A (0.46) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL13187875 | 0.87 | ALDH1A1 (0.55) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL2703833 | 0.87 | CARM1 (0.48) | CA12CA1CA2CA9KDM1A | |
| SCHEMBL16676932 | 0.86 | ALDH1A1 (0.54) | CA12CA1CA2CA9KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119438590-A | Method for in-situ labelling lysosomal protein in living cell and reagent used in same | 北京大学 | 2025-02-14 | — | — | CN | claimed |
| CN-119438590-A | Method for in-situ labelling lysosomal protein in living cell and reagent used in same | 北京大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240199788-A1 | METHOD OF PRODUCING MORPHOLINE CATALYSTS FOR RIGID FOAM SYSTEMS AND USES THEREOF | HUNTSMAN PETROCHEMICAL LLC | 2024-06-20 | — | — | US | disclosed |
| EP-4323325-A1 | METHOD OF PRODUCING MORPHOLINE CATALYSTS FOR RIGID FOAM SYSTEMS AND USES THEREOF | Huntsman Petrochemical LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-110922437-B | Glucose compound, pharmaceutical composition and application thereof | 凯惠科技发展(上海)有限公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2022221041-A1 | METHOD OF PRODUCING MORPHOLINE CATALYSTS FOR RIGID FOAM SYSTEMS AND USES THEREOF | HUNTSMAN PETROCHEMICAL LLC (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-110922437-A | Glucose compound, pharmaceutical composition and application thereof | 凯惠科技发展(上海)有限公司 | 2020-03-27 | — | — | CN | disclosed |
| WO-2020057605-A2 | GLUCOSE COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 凯惠科技发展(上海)有限公司 | 2020-03-26 | — | — | WO | disclosed |
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | MITSUI CHEMICALS, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1090031-A1 | SUBSTITUTED CYCLOOCTADEPSIPEPTIDES | Bayer Aktiengesellschaft (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067281-A1 | SUBSTITUTED CYCLOOCTADEPSIPEPTIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | WO | disclosed |
| US-4895840-A | ANTIARRHYTHMIA AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0295010-A1 | Derivatives of alkylaminoalkyl ureas and cyanoguanidines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306376-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED FOR THE SAME | CACNA1B, KCNN4, KCNN2 | CA12 717/4885CA1 174/4885CA2 182/4885 |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | CA12 2313/4885CA1 2699/4885CA2 2017/4885 |
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | CA12 4785/4885CA1 4313/4885CA2 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.